Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

NCT07227909 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT07227909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 4, 2026
Completion date
January 31, 2031
Enrollment
83 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathy, psilocybin